(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.5%.
Centessa Pharmaceuticals's earnings in 2026 is -$242,698,000.On average, 17 Wall Street analysts forecast CNTA's earnings for 2026 to be -$224,810,227, with the lowest CNTA earnings forecast at -$266,152,936, and the highest CNTA earnings forecast at -$196,226,617. On average, 16 Wall Street analysts forecast CNTA's earnings for 2027 to be -$242,234,666, with the lowest CNTA earnings forecast at -$280,646,413, and the highest CNTA earnings forecast at -$200,461,723.
In 2028, CNTA is forecast to generate -$155,999,824 in earnings, with the lowest earnings forecast at -$354,431,385 and the highest earnings forecast at $175,051,082.